SGLT2 inhibitors were linked to a reduced likelihood of composite anemia outcomes, particularly instances of anemia events. 

This retrospective cohort study, indicated that using SGLT2 inhibitors was associated with a 19% reduced risk of composite anemia outcomes compared to the use of GLP-1 RA. 

The results remained consistent across various SGLT2 inhibitors, implying a class-wide effect of anemia benefits associated with SGLT2 inhibitors. 

These main findings were supported by alterations in hematological laboratory parameters, revealing significant distinctions between the SGLT2 inhibitor and GLP-1 RA groups over the three-year monitoring period. 

The similarity in glycemic control and kidney function changes observed in both the SGLT2 inhibitor and GLP-1 RA groups suggest that mechanisms possibly responsible for the decreased incidence of anemia with SGLT2 inhibitor use are likely independent of these factors. 

SGLT2 inhibitors may be considered as an adjunct therapy to mitigate the occurrence of mitigate the occurrence of anemia in patients with type 2 diabetes and chronic kidney disease. 

 

Reference:
Hu J, et al. Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD. JAMA Netw Open. 2024;7(3):e240946.